Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Johnson and Johnson
McKesson
Express Scripts

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)

Docket   Start Trial Date Filed 2018-06-28
Court District Court, D. Delaware Date Terminated
Cause 35:271 Patent Infringement Assigned To Mitchell S. Goldberg
Jury Demand None Referred To
Parties ACCORD HEALTHCARE, INC.; AMGEN INC.; INTAS PHARMACEUTICALS LIMITED
Patents 6,011,068; 6,211,244; 6,316,460; 6,495,165; 6,733,780; 6,862,890; 7,829,595; 8,288,434; 9,375,405
Attorneys Aaron F. Barkoff; Alejandro Menchaca; Benjamin J. Schladweiler; Derek James Fahnestock; Eric M. Agovino; Jack B. Blumenfeld; Lois Kwasigroch; Lois M. Kwasigroch; Maryellen Noreika; Wendy A. Whiteford
Firms Greenberg Traurig, the Nemours Building; Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Amgen Inc. v. Accord Healthcare, Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Amgen Inc. v. Accord Healthcare, Inc.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Amgen Inc. v. Accord Healthcare, Inc. (D. Del. 2018)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 Complaint action for infringement of U.S. Patent No. 9,375,405 (the “’405 patent”) (Exhibit A). … THE PATENT-IN-SUIT 14. On June 28, 2016, the ’405 patent, titled “Rapid …United States Patent and Trademark Office (“PTO”). 15. The ’405 patent is assigned to…the ’405 patent when Accord notified Amgen of its Paragraph IV Certification of the ’405 patent. …expiration of the ’405 patent will constitute an act of infringement of the ’405 patent. B External link to document
0000-00-00 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,375,405 B2. (nmg) (Entered:… 28 June 2018 1:18-cv-00956 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 66 Claim Construction Chart for the asserted claims of U.S. Patent No. 9,375,405 (“the ’405 patent”). In order to narrow … e.g., ’405 patent, col.6 l.57- the ’405 patent, …: See, patent at Fig. 1, 6:57- e.g., ’405 patent, col.6 8…Evidence2 Intrinsic Evidence2 ’405 patent, “from about 1% to about “from about 1% to about… composition may contain patent at Fig. 1, 6:57- External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
McKesson
Medtronic
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.